// App-Quantinova.ai

: Blinatumomab Alternating With Low-Intensity Chemotherapy (CT) Treatment for Older Adults With Newly Diagnosed Philadelphia (Ph)-Negative B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) is Well Tolerated and Efficacious: Safety Run-In Results for the Phase 3 Randomized Controlled Golden Gate Study

Researchers

Presenter

  • Elias Jabbour

Principal Investigators

  • Ibrahim Aldoss

  • Shaun Fleming

  • Ashish Bajel

  • Paul Cannell

  • Monika Bruggemann

  • Gerhard Zugmaier

  • Joan Morris

  • Yuqi Chen

  • Sonny Powar

  • Hansen Wong

  • Bjorn Steffen

  • Hagop Kantarjian

  • Nicola Goekbuget

Medical Centers

  • City of Hope, Duarte, CA

  • Department of Medicine II, Hematology/Oncology, Goethe University Hospital, Frankfurt, Germany

  • THe Alfred, Melbourne, Australia

  • University Medical Center Schleswig-Holstein, Kiel, Germany

  • Fiona Stanley Hospital, MURDOCH, Australia

  • Department of Medicine II, Goethe University, University Hospital, Frankfurt, Germany

  • MD ANDERSON CANCER CENTER, HOUSTON, TX

  • Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia

Locations

  • United States

  • Australia

  • Germany

  • United Kingdom

Companies

  • Amgen Inc.

  • AMGEN Research (Muni

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • B-lymphocyte antigen CD20

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Blinatumomab

  • Hydroxyurea

  • Hydroxycarbamide

  • Vincristine

  • Rituximab

Outcome

  • N/A

Study Design

  • Randomized

  • Efficacy

  • Safety

  • Pharmacokinetics

  • Tolerability

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved